Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Avrobio Inc (AVRO)

Avrobio Inc (AVRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 54,282
  • Shares Outstanding, K 44,861
  • Annual Sales, $ 0 K
  • Annual Income, $ 12,160 K
  • 60-Month Beta 1.22
  • Price/Sales N/A
  • Price/Cash Flow 4.19
  • Price/Book 0.56
Trade AVRO with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.57
  • Growth Rate Est. (year over year) +175,363.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1500 +3.48%
on 03/25/24
1.3100 -9.16%
on 04/05/24
-0.0900 (-7.03%)
since 03/22/24
3-Month
1.0100 +17.82%
on 01/30/24
1.3700 -13.14%
on 01/29/24
-0.1400 (-10.53%)
since 01/24/24
52-Week
0.5700 +108.77%
on 05/17/23
1.7000 -30.00%
on 05/22/23
+0.2899 (+32.21%)
since 04/24/23

Most Recent Stories

More News
AVROBIO Announces Leadership Transition

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced the appointment of Erik Ostrowski as interim Chief...

AVRO : 1.1900 (-1.65%)
AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update

AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the fourth quarter and year...

AVRO : 1.1900 (-1.65%)
AVROBIO to Participate in Cowen’s 43rd Annual Health Care Conference

AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled...

AVRO : 1.1900 (-1.65%)
AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposiumâ„¢ 2023

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that updated data suggesting complete biochemical...

AVRO : 1.1900 (-1.65%)
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 7,500...

AVRO : 1.1900 (-1.65%)
AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced new interim pharmacokinetic, pharmacodynamic and...

AVRO : 1.1900 (-1.65%)
AVROBIO to Share Comprehensive Gaucher Disease Program Update

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it will host a virtual Gaucher Disease Program...

AVRO : 1.1900 (-1.65%)
AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update

AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the third quarter ended Sept....

AVRO : 1.1900 (-1.65%)
AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy Summit

AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced senior management will be participating in a virtual...

AVRO : 1.1900 (-1.65%)
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVROBIO , Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 13,000...

AVRO : 1.1900 (-1.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Avrobio, Inc. is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc. is based in MA, United States.

See More

Key Turning Points

3rd Resistance Point 1.2300
2nd Resistance Point 1.2200
1st Resistance Point 1.2050
Last Price 1.1900
1st Support Level 1.1800
2nd Support Level 1.1700
3rd Support Level 1.1550

See More

52-Week High 1.7000
Fibonacci 61.8% 1.2683
Last Price 1.1900
Fibonacci 50% 1.1350
Fibonacci 38.2% 1.0017
52-Week Low 0.5700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar